Phase II Neoadjuvant Pyrotinib Combined with Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

NCT05165225 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Breast Cancer
HER2-low-expressing Breast Cancer
Hormone Receptor-positive Breast Cancer
Neoadjuvant Therapy

Interventions

DRUG: Pyrotinib + epirubicin and cyclophosphamide followed by docetaxel treatment

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Collaborators

[object Object]